Pharmacological profile of a new psychotherapeutic agent: 4-p-fluorophenyl-5-N(N'-o-methoxyphenyl)piperazinoethyl-4-oxazolin-2-one (LR 511).
D000374:Aggression / Q000187:drug effects; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D002375:Catalepsy / Q000188:drug therapy; D003213:Conditioning, Psychological / Q000187:drug effects; D004285:Dogs; D004357:Drug Synergism; D005106:Exploratory Behavior / Q000187:drug effects; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D010080:Oxazoles / Q000008:administration & dosage / Q000494:pharmacology*; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D014149:Tranquilizing Agents / Q000494:pharmacology
D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents; D006993:Hypnotics and Sedatives; D010080:Oxazoles; D010879:Piperazines; D011619:Psychotropic Drugs; D014149:Tranquilizing Agents; C015599:LR 511